Statement of Principles concerning methaemoglobinaemia (Reasonable Hypothesis) (No. 17 of 2019)

The central legal concept is the “reasonable hypothesis” standard. This is not defined in the SoP itself, but derives from sections 120(1) and 120A of the VEA. It means that for a claim to succeed, the material before the decision-maker must raise a hypothesis that is reasonable, meaning it is pointed to by the facts, is not fanciful, and is consistent with the template contained in the SoP. The SoP is the mechanism that operationalises that standard: once the RMA has determined the factors, a reasonable hypothesis cannot be raised unless at least one factor exists and relates to service (s 9 read with s 10). The SoP itself is the product of the RMA’s assessment of “sound medical‑scientific evidence” (s 8), and that recital is not open to challenge on the merits except on limited judicial review grounds. Thus, the SoP creates a quasi‑legislative fact‑finding that binds decision‑makers.

Another key concept is the definition of methaemoglobinaemia in s 7(2). It is narrower than the ICD‑10‑AM code D74 (s 7(3) provides that while the condition attracts that code, the SoP’s own definition governs). The inclusion of the heterozygous form of NADH-methaemoglobin reductase deficiency restricted to red blood cells, but exclusion of other congenital forms, is a deliberate carve‑out. This means that a person with a congenital enzyme deficiency that is not restricted to red blood cells cannot rely on the SoP to link that condition to service. This is a substantive limitation on coverage.

The factors themselves (s 9) are based on the concept of “oxidation of haemoglobin”. The notes to factors 1 and 2 provide non‑exhaustive lists: drugs such as dapsone, primaquine, tafenoquine, chloroquine, nitrates (nitroglycerine), nitrites (amyl nitrite), benzocaine, and sulphonamide antibiotics; chemicals such as aniline derivatives, naphthalene, nitrobenzenes, nitrogen oxide, paraquat, chlorates, nitrates and nitrotoluenes. The two‑day window for both onset and worsening sets a very tight temporal link. Factor 9 (“inability to obtain appropriate clinical management”) has no time limit but will require proof that appropriate management was not available or was denied, which raises factual and evidentiary issues.

The instrument also distinguishes between clinical onset and clinical worsening. Factors 1-4 apply to the initial occurrence; factors 5-8 apply where the condition already existed and then worsened. Section 10(2) provides that factors 5-9 apply only to material contribution to or aggravation of methaemoglobinaemia where the person’s methaemoglobinaemia was suffered or contracted before or during (but did not arise out of) the person’s relevant service. This limits the aggravating factors to cases where the condition pre‑existed service or arose during service from a non‑service cause.

Finally, the dictionary defines “relevant service” as operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. The SoP does not cover peacetime service under the VEA (domestic service not on operations) unless it falls within one of those categories. It also defines “terminal event” for death cases, including pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function, provided the terminal event was contributed to by the methaemoglobinaemia.

The primary class of persons affected is veterans and members of the Australian Defence Force who have rendered “relevant service” as defined in the Schedule 1 dictionary. That means those who have undertaken operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. These are the only service types that can ground a claim for methaemoglobinaemia or death from it. Veterans with peacetime domestic service (e.g., training or administrative work in Australia) are excluded unless that service is captured as hazardous or operational. Also covered are members of Peacekeeping Forces and members of the Forces (the latter being a term used in the VEA). The instrument does not extend to the families of veterans directly (e.g., dependants claiming in their own right), but they may be affected indirectly if they are claiming as dependants in respect of a veteran’s death. The instrument applies to claims made under s 120A VEA or s 338 MRCA,so it affects anyone who has lodged or will lodge a claim for a service‑related condition, whether for pension, compensation, or other benefits under those Acts.

Decision‑makers are directly affected: delegates of the Repatriation Commission, the Military Rehabilitation and Compensation Commission, and the Veterans’ Review Board (VRB) and the Administrative Appeals Tribunal (AAT) must apply this SoP when determining claims. They cannot rely on general medical evidence or alternative causal theories unless the SoP is satisfied. The instrument reduces their discretion by providing a prescriptive list. However, they retain the role of fact‑finding: they must be satisfied on the balance of probabilities that the claimed factor exists (though for the reasonable hypothesis stage, the standard is lower). The RMA itself is the body that creates and updates SoPs; it is affected as it must determine whether new evidence warrants amendment (but the 2019 SoP is the current one).

Medical professionals are affected in a practical sense: when asked to provide reports for claims, they must be aware of the defined disease, the list of drugs and chemicals, and the two‑day timing. Reports that opine causation based on other evidence (e.g., longer latency or different mechanisms) may be rejected if they do not match a factor. This can create a tension between clinical judgment and the instrument’s constraints. For example, a doctor might consider that occupational exposure to aniline dyes over weeks caused methaemoglobinaemia, but the SoP requires exposure within two days of onset, potentially excluding that claim unless the onset can be linked to a specific acute event within that window.

Legal practitioners, advocates, and claims officers must be familiar with the list of factors to advise clients or determine claims. The instrument also affects other people indirectly: for example, suppliers of medical services (e.g., dialysis clinics) might face claims if their procedures expose veterans to contaminated dialysis fluid (factor 4). Finally, the Australian taxpayer ultimately bears the cost of successful claims, so the SoP has a fiscal impact by determining eligibility for disability pensions and compensation payments. The more factors are listed and the broader the definitions, the greater the potential number of accepted claims.

The SoP does not create duties in the traditional sense. Instead, it establishes rights for claimants to have their claim assessed using the reasonable hypothesis standard, provided they can demonstrate that at least one of the factors in s 9 exists and is related to relevant service. The duty on the decision-maker is to apply the SoP: they must treat the factors as the exclusive means by which a reasonable hypothesis can be raised. If a claimant cannot point to one of the listed factors, the claim must fail at the reasonable hypothesis stage, regardless of other medical evidence. If a factor is made out, the decision-maker must then consider whether the contrary proof standard (reasonable satisfaction) displaces the hypothesis.

Claimants have the right to rely on the notes to s 9, which give examples of drugs and chemicals that cause methaemoglobinaemia. However, those notes are non‑exhaustive: “including, but not limited to”. This means a claimant may rely on an agent not listed, provided they can prove it causes oxidation of haemoglobin. The decision-maker has a duty to consider whether unlisted agents fall within the factor’s scope. This creates a degree of flexibility, but also potential for dispute over whether a particular substance meets the criterion. The explicit examples (dapsone, primaquine, nitrates, nitrites, etc.) are likely to be accepted without further evidence; others will require expert medical opinion.

The SoP also creates a duty on the part of the Repatriation Medical Authority under s 196B of the VEA to only determine factors where there is sound medical‑scientific evidence (s 8 recites that they are of that view). That is a duty of care in the exercise of statutory power, but it is not enforceable by individual claimants other than through judicial review for jurisdictional error. Once the SoP is made, it is binding.

For clinical worsening claims (factors 5-8 and factor 9), s 10(2) imposes a duty on the claimant to show that the methaemoglobinaemia was suffered or contracted before or during (but did not arise out of) the relevant service. In other words, the condition must have pre‑existed or arisen from a non‑service cause during service, and the claimed service factor must have materially contributed to or aggravated it. This restricts the scope of aggravation claims.

Claimants have a right to have claims determined in accordance with the SoP as in force at the time of the decision (s 5 applies to claims to which s 120A VEA or s 338 MRCA applies). There is no right to have the SoP reviewed on its merits; it is a legislative instrument that can only be challenged on administrative law grounds (e.g., ultra vires, unreasonableness). Practically, the right is to have the decision‑maker consider the application of the relevant factor and to be given reasons.

An important duty on decision‑makers arises from s 11: if a factor in s 9 refers to an injury or disease covered by another Statement of Principles determined under s 196B(2) VEA, then the factors in that other SoP apply in accordance with its terms as in force from time to time. This cross‑referencing means that, for example, if a factor requires that the person was taking a drug for a condition that itself is covered by a SoP, the claimant must also satisfy that other SoP. Decision‑makers must be aware of the network of SoPs.

This instrument contains no penalties of its own. It is not a penal statute; it is an evidentiary standard for determining claims. However, false or misleading statements made in connection with a claim under the VEA or MRCA could attract penalties under those Acts or under the Criminal Code. For example, giving false information to obtain a pension or compensation may constitute an offence under s 135.1 of the Criminal Code (obtaining a financial advantage by deception) or under specific provisions of the VEA (ss 221-226 create offences for making false statements). The SoP itself does not create any offence.

Enforcement of the SoP is not through prosecution but through the administrative review and judicial review system. If a decision‑maker fails to apply the SoP correctly, the claimant can seek review: first internally (by requesting reconsideration under s 31 VEA or equivalent MRCA processes), then to the Veterans’ Review Board (VRB), then to the Administrative Appeals Tribunal (AAT), and finally to the Federal Court on a question of law. The AAT can set aside the decision and substitute its own, but it must apply the SoP. If a decision‑maker applies the SoP incorrectly (e.g., misinterprets “methaemoglobinaemia” as including congenital forms), that is an error of law and may be overturned. The Repatriation Medical Authority itself is not directly subject to enforcement; its SoP is a legislative instrument that can be disallowed by Parliament (under the Legislation Act 2003) or challenged for exceeding the regulation‑making power. However, such challenges are rare and expensive.

The practical enforcement risk for claimants is that if they fail to prove a factor exists, they get no benefit. There is no fine or punishment. For decision‑makers, failure to apply the SoP correctly may lead to a decision being overturned on review, which may have cost implications for the government if it is ordered to pay the claim plus costs (though in the AAT, costs generally are not awarded). There is also potential for the Commonwealth Ombudsman or the Inspector‑General of the Australian Defence Force to investigate systemic maladministration, but this is not specific to the SoP.

As an economic matter, the SoP functions as a gatekeeper for public expenditure. Any error that erroneously allows a claim that does not meet the factors (i.e., a false positive) imposes a cost on the compensation scheme and ultimately on taxpayers. Conversely, erroneous rejection of a valid claim may impose costs on the veteran or their family. The SoP’s structure (tight two‑day windows, exclusive definitions) is designed to minimise false positives, but it may also result in false negatives. There are no penalties to deter the decision‑maker from erring in either direction, other than internal performance metrics and the possibility of external review. The enforcement mechanism is thus entirely reactive.

This SoP is made under s 196B(2) of the Veterans’ Entitlements Act 1986. It is a legislative instrument subordinate to that Act. The VEA itself provides the overarching framework for claims, including the standard of proof (reasonable hypothesis followed by reasonable satisfaction) and the role of SoPs. Section 120A of the VEA requires that, for claims relating to disease, the Commission must be satisfied that the disease is a war‑caused disease or defence‑caused disease, and in doing so must have regard to the relevant SoP. The SoP is thus the interpretive prism through which the VEA’s causation test is applied for methaemoglobinaemia.

The SoP also interacts with the Military Rehabilitation and Compensation Act 2004 (MRCA). Section 338 of the MRCA in turn requires that for a disease claim under that Act, the Commission must have regard to SoPs determined under the VEA. So this SoP applies equally to claims under MRCA for warlike and non‑warlike service. Consequently, the instrument creates a single uniform standard across the two compensation schemes, reducing the risk of different outcomes for the same condition depending on which Act applies. However, the MRCA also has its own definitions of service types (warlike and non‑warlike) which align with the SoP’s definition of “relevant service” (Schedule 1).

The instrument explicitly defines methaemoglobinaemia by reference to ICD‑10‑AM code D74, Tenth Edition (effective 1 July 2017). This coding system is used for administrative purposes (hospital data, morbidity classification) but the SoP makes clear that the code is merely a reference point and the SoP’s own definition governs (s 7(3)). Thus, if the ICD‑10‑AM is updated to include a broader or narrower definition, the SoP remains unchanged unless the RMA amends it. This reflects a deliberate choice to control the definition independently of external coding changes, which could otherwise inadvertently expand or contract coverage.

The SoP interacts with other SoPs through s 11. If a factor refers to an injury or disease for which another SoP exists (e.g., if factor 1 refers to taking dapsone for leprosy, which is itself a disease covered by a SoP), the decision‑maker must also apply that other SoP. This prevents a claimant from relying on a factor that involves an underlying condition unless that underlying condition is also service‑related. This cross‑linking can create cascading evidentiary requirements.

The instrument also interacts with the general law of evidence and administrative law. The decision‑maker must assess the existence of factors on the evidence, applying the usual rules of proof (balance of probabilities for factual findings, but the reasonable hypothesis standard allows a lower threshold for the overall hypothesis). The SoP does not displace the requirement for a decision‑maker to consider all the material,it merely dictates that if no factor exists, the claim must fail. Lastly, the SoP may interact with state workers’ compensation schemes or the Safety, Rehabilitation and Compensation Act 1988 (SRCA) for Defence Force members, but those schemes typically have their own causation rules and are not bound by this SoP. Veterans who elect to claim under the SRCA instead of the VEA or MRCA may not be able to rely on this SoP; they must use the SRCA’s own disease provisions.

This instrument, No. 17 of 2019, repeals and replaces the earlier Statement of Principles concerning methaemoglobinaemia No. 47 of 2010 (s 4). The 2010 SoP was itself a replacement of earlier versions. The instrument records its commencement date as 25 March 2019 (s 2). The RMA determined it under s 196B(2) VEA, meaning it is a “reasonable hypothesis” SoP (as opposed to a “reasonable satisfaction” SoP made under s 196B(3) for cases where the contrary proof standard is not met). The 2019 version updated the scientific evidence base and potentially revised the list of factors, the definition, or the examples. However, the text of the 2010 SoP is not reproduced here, so we cannot compare specific changes. The instrument’s note to s 8 indicates that the RMA is of the view that there is sound medical‑scientific evidence that indicates the condition can be related to relevant service. This is a standard recital and is not a change.

The dictionary definitions have been updated to include the MRCA references and the current ICD‑10‑AM edition (10th edition, 2017). The 2010 SoP likely used a prior edition. The factor list now explicitly includes “taking or being treated with a drug” and “inhaling, ingesting or having cutaneous contact with a chemical agent” with updated examples. The 2010 SoP may have had fewer examples or different chemical lists. The two‑day window appears unchanged, as does the exclusion of most congenital forms. Factor 9 (“inability to obtain appropriate clinical management”) appears in both versions. The key structural change may be the treatment of clinical worsening: factors 5-8 explicitly mirror 1-4 for worsening, and s 10(2) clarifies that they apply only where the condition existed before or during service but did not arise out of service. This may be a clarification rather than a substantive change.

The instrument also now includes a section 11 on cross‑referencing other SoPs, which may have been added or refined. The version history matters for claimants: if a claim was lodged before 25 March 2019, the 2010 SoP applied; if after, the 2019 SoP applies. Transitional provisions are not included in this instrument, but the VEA and MRCA contain rules about when the instrument in force at the time of the decision applies (or at the time of the claim). Practitioners must check which version governs. The RMA typically reviews SoPs periodically; the 2019 version may be reviewed in the future if new evidence emerges, particularly regarding drugs or chemicals. The amendment history highlights that SoPs are not static; they evolve with medical science. Each revision creates a potential vested right or defeats an existing claim depending on timing.

The source does not cite any specific cases, and we must not invent them. However, we can discuss the broader litigation context. Statements of Principles are frequently litigated in the Administrative Appeals Tribunal (AAT) and the Federal Court. The key issues in methaemoglobinaemia cases would likely be: whether the claimed drug or chemical falls within the factor (e.g., is a particular substance an “oxidising agent”?); whether the two‑day window is met; whether the definition of methaemoglobinaemia under s 7(2) is satisfied (especially the exclusion of other congenital forms); and whether “inability to obtain appropriate clinical management” (factor 9) is made out. The AAT has considered similar SoPs for other diseases and has developed principles about the application of the reasonable hypothesis standard. For example, the AAT may have held that the notes are not exhaustive and the decision‑maker must consider other evidence.

The reasonable hypothesis standard itself is well‑established in case law: the leading authority is Repatriation Commission v Deledio (1998) 83 FCR 82, which sets out a four‑step approach: (1) identify the hypothesis; (2) check whether the SoP specifies a factor; (3) if so, consider whether the hypothesis fits the template; (4) if so, consider whether there is contrary proof beyond reasonable doubt. This SoP operates at step 2 and 3. Cases would interpret the meaning of “clinical onset” and “clinical worsening”, and whether a factor existed on the facts. There may also be disputes about the definition of “relevant service” and whether a particular service qualifies as “hazardous” or “non‑warlike”. The dictionary definitions are from the VEA and MRCA, so those cases would involve interpretation of those Acts.

No specific High Court or Federal Court decisions on methaemoglobinaemia SoP are recorded publicly in a way that is evident from this instrument. The RMA’s recital of “sound medical‑scientific evidence” is rarely challenged successfully, but there have been cases where the Federal Court has found that a SoP was ultra vires because the RMA did not have a sufficient evidentiary basis (e.g., in other contexts). However, those challenges are difficult.

For practitioners, awareness of the case law on analogous SoPs (e.g., for other blood disorders) is useful because the approach to interpreting factors, the two‑day window, and the clinical onset timing is likely similar. The AAT decisions are not binding but are persuasive. The litigation history shows that the reasonable hypothesis standard is a relatively low threshold for claimants to get past the first stage, but the SoP itself can be an obstacle if the facts don’t fit. The 2019 SoP may have been revised in light of earlier litigation to clarify definitions (e.g., the exclusion of other congenital forms is now explicit). Without case citations, we can only note that the field is actively litigated.

Several traps exist for the unwary:

1. The two‑day window is extremely tight (s 9 factors 1-8). A claimant who was exposed to a chemical or drug more than two days before the onset will not satisfy the factor, even if the substance is a known cause of methaemoglobinaemia. This is a harsh rule given that some drugs (e.g., dapsone) have a long half‑life and may accumulate. The instrument does not account for chronic low‑level exposure that eventually triggers symptoms; only an acute exposure within two days of onset counts. For clinical worsening, the same two‑day window applies to the worsening event, not the initial onset.

2. The definition of methaemoglobinaemia excludes “other forms of congenital methaemoglobinaemia” (s 7(2)(c)). This means that if a person has a congenital deficiency of NADH‑methaemoglobin reductase that is not restricted to red blood cells, they cannot claim under this SoP. Even if their condition is worsened by service factors, the SoP only covers the heterozygous form restricted to red blood cells. A veteran with a more systemic congenital deficiency will be unable to get service‑relatedness recognised, regardless of exposure.

3. The “inability to obtain appropriate clinical management” factor (factor 9) has no time limit, but it requires proof that appropriate management was not obtained. This could be difficult if the veteran had access to medical care but chose not to seek it, or if the management was inappropriate but alternatives existed. The factor is often used as a catch‑all but may be narrowly interpreted. It also applies only to material contribution or aggravation (s 10(2)), so it cannot establish initial onset.

4. The notes to s 9 are non‑exhaustive but influential. A decision‑maker may be tempted to treat them as exhaustive if the evidence is thin. Claimants should not rely solely on the listed examples; but they must still prove the unlisted substance causes oxidation of haemoglobin. This requires medical evidence, which adds cost and time.

5. The definition of “relevant service” excludes peacetime domestic service unless it falls under hazardous or operational categories. A reservist who develops methaemoglobinaemia from chemical exposure during a training exercise may not have “relevant service” if the exercise is not classified as hazardous or operational. The SoP does not cover full‑time service in Australia that is not operational.

6. Death claims are covered only if the terminal event (e.g., respiratory failure) was contributed to by the methaemoglobinaemia (s 7(5) read with dictionary definition of “terminal event”). If the immediate cause of death is unrelated (e.g., motor vehicle accident), even if the veteran also had methaemoglobinaemia, it will not be considered death from methaemoglobinaemia.

7. Section 11 creates a trap: if a factor refers to an injury or disease covered by another SoP, that SoP must also be satisfied. For example, factor 1 includes “taking a drug that causes oxidation of haemoglobin”. If that drug was prescribed for a condition like depression, and depression has its own SoP, the decision‑maker must also apply the depression SoP. This can create a cascade of requirements that defeat the claim even though the drug exposure itself is conceded.

8. The effective date of the SoP is 25 March 2019 (s 2). Claims made before that date are governed by the repealed SoP No. 47 of 2010, which may have different definitions or factors. A practitioner must check which SoP applies based on the date of claim or decision.

Compliance with this SoP is not about obeying a regulation but about navigating a claims process. For a claimant (veteran or member) to succeed in having methaemoglobinaemia accepted as service‑related, they must ensure that their claim and supporting evidence addresses each element of the applicable factor. The following steps are practical:

First, obtain a definitive diagnosis that fits the SoP definition. The diagnosis must be “a greater than normal amount of methaemoglobin in the blood as a result of the oxidation of haem iron to the ferric state”, causing clinical manifestations like cyanosis, headache or fatigue. It must not be a congenital form excluded by s 7(2)(c). A laboratory result showing elevated methaemoglobin is essential, and the treating doctor should confirm the aetiology (acquired or heterozygous red‑cell‑restricted deficiency). If the diagnosis is unclear, a specialist haematologist opinion is advisable.

Second, identify which factor in s 9 applies. The most common factors are 1 (drug) and 2 (chemical). Check the lists of examples but be prepared to prove the substance causes oxidation of haemoglobin if it is not listed. For drugs, a prescription record or medication chart showing administration within two days before onset is critical. For chemicals, an exposure history linking the substance to the two‑day window is needed. For contaminated food/water (factor 3) or dialysis fluid (factor 4), documentary evidence of contamination (e.g., water quality reports, incident reports) should be gathered. For clinical worsening (factors 5-8), show evidence of the baseline condition (previous medical records) and a worsening that occurred within two days of the new exposure.

Third, if factor 9 is relied upon (inability to obtain appropriate clinical management), evidence is needed that appropriate management (e.g., administration of methylene blue, vitamin C, or exchange transfusion) was not available, was denied, or was not provided in a timely manner. This may require service medical records showing what was or was not done, and expert opinion on what would have been appropriate.

Fourth, establish that the factor is related to the person’s relevant service. The exposure or the failure of clinical management must have occurred during the period of relevant service or be causally connected to it. For operational service, most exposures during deployment will qualify. For hazardous service, the nature of the hazard must be proven. A statement of service history and details of duties is essential.

Fifth, be aware of the two‑day window: the date of clinical onset and the date of the exposure must be precisely established. Medical records showing the date of first symptoms, and a log of drug administration or chemical contact, are crucial. If the onset date is unclear, the claim may fail.

Sixth, for death claims, show that the terminal event (pneumonia, respiratory failure, etc.) was contributed to by the methaemoglobinaemia (s 7(5)). A death certificate and autopsy report (if available) can help establish this.

Seventh, consider the interaction with other SoPs (s 11). If the factor involves a disease for which another SoP exists (e.g., taking dapsone for dermatitis herpetiformis), the claimant must also satisfy that other SoP’s factors. This may require separate evidence linking the underlying disease to service.

Finally, ensure the claim is lodged under the correct Act (VEA or MRCA) and that the service type matches the definition of “relevant service”. If the veteran has both VEA and MRCA service, advice should be sought on which claim offers the best chance. The decision‑maker, when assessing, must apply the SoP in force at the date of the decision (or the date of claim depending on transitional provisions). Thus, the claimant’s representative should check the current version. All evidence must be contemporary and as specific as possible. Generic claims that a veteran “may have been exposed” will not satisfy the high evidentiary burden required to prove the existence of the factor on the facts. The SoP lowers the causation threshold (reasonable hypothesis) but does not lower the need for proof of the underlying factual events.